Details

Autor(en) / Beteiligte

• Angstwurm, Matthias W. A
• Engelmann, Lothar
• Zimmermann, Thomas
• Lehmann, Christian
• Spes, Christoph H
• Abel, Peter
• Strauß, Richard
• Meier-Hellmann, Andreas
• Insel, Rudolf
• Radke, Joachim
• Schüttler, Jürgen
• Gärtner, Roland

Titel

Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock

Ist Teil von

• Critical care medicine, 2007-01, Vol.35 (1), p.118-126

Ort / Verlag

Hagerstown, MD: Copyright by by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• OBJECTIVE:Sepsis is associated with an increase in reactive oxygen species and low endogenous antioxidative capacity. We postulated that high-dose supplementation of sodium-selenite would improve the outcome of patients with severe sepsis and septic shock. DESIGN:Prospective randomized, placebo-controlled, multiple-center trial. SETTING:Eleven intensive care units in Germany. PATIENTS:Patients were 249 patients with severe systemic inflammatory response syndrome, sepsis, and septic shock and an Acute Physiology and Chronic Health Evaluation (APACHE) III score >70. INTERVENTIONS:Patients received 1000 μg of sodium-selenite as a 30-min bolus injection, followed by 14 daily continuous infusions of 1000 μg intravenously, or placebo. MEASUREMENTS AND MAIN RESULTS:The primary end point was 28-day mortality; secondary end points were survival time and clinical course of APACHE III and logistic organ dysfunction system scores. In addition, selenium levels in serum, whole blood, and urine as well as serum gluthation-peroxidase-3 activity were measured. From 249 patients included, 11 patients had to be excluded. The intention-to-treat analysis of the remaining 238 patients revealed a mortality rate of 50.0% in the placebo group and 39.7% in the selenium-treated group (p = .109; odds ratio, 0.66; confidence interval, 0.39–1.1). A further 49 patients had to be excluded before the final analysis because of severe violations of the study protocol. In the remaining 92 patients of the study group, the 28-day mortality rate was significantly reduced to 42.4% compared with 56.7% in 97 patients of the placebo group (p = .049, odds ratio, 0.56; confidence interval, 0.32–1.00). In predefined subgroup analyses, the mortality rate was significantly reduced in patients with septic shock with disseminated intravascular coagulation (n = 82, p = .018) as well as in the most critically ill patients with an APACHE III score ≥102 (>75% quartile, n = 54, p = .040) or in patients with more than three organ dysfunctions (n = 83, p = .039). Whole blood selenium concentrations and glutathione peroxidase-3 activity were within the upper normal range during selenium treatment, whereas they remained significantly low in the placebo group. There were no side effects observed due to high-dose sodium-selenite treatment. CONCLUSIONS:The adjuvant treatment of patients with high-dose sodium-selenite reduces mortality rate in patients with severe sepsis or septic shock.